Esperion Therapeutics Inc (NASDAQ: ESPR)’s stock price has soared by 1084672 in relation to previous closing price of 1.04. Nevertheless, the company has seen a loss of -9.40% in its stock price over the last five trading days. seekingalpha.com reported 2025-06-14 that Esperion’s recent rebound is driven by stronger-than-expected prescription growth, revived business momentum after Medicare coverage issues subsided, and good news flow from investor conferences. Management projects profitability by Q1 2026, but I am wary given current revenue, cash, and expense guidance—profitability claims seem optimistic without a clear revenue boost. Pipeline developments, including a triple-combo LDL-C pill and liver/kidney therapies, could be transformative, but near-term catalysts hinge on execution and proof of profitability.
Is It Worth Investing in Esperion Therapeutics Inc (NASDAQ: ESPR) Right Now?
The 36-month beta value for ESPR is also noteworthy at 0.67. There are mixed opinions on the stock, with 2 analysts rating it as a “buy,” 2 rating it as “overweight,” 2 rating it as “hold,” and 0 rating it as “sell.”
The public float for ESPR is 194.62M, and at present, short sellers hold a 13.54% of that float. The average trading volume of ESPR on June 24, 2025 was 5.26M shares.
ESPR’s Market Performance
ESPR’s stock has seen a -9.40% decrease for the week, with a 32.00% rise in the past month and a -39.08% fall in the past quarter. The volatility ratio for the week is 3.27%, and the volatility levels for the past 30 days are at 4.63% for Esperion Therapeutics Inc The simple moving average for the last 20 days is -0.81% for ESPR’s stock, with a simple moving average of -39.20% for the last 200 days.
Analysts’ Opinion of ESPR
Many brokerage firms have already submitted their reports for ESPR stocks, with Goldman repeating the rating for ESPR by listing it as a “Neutral.” The predicted price for ESPR in the upcoming period, according to Goldman is $4 based on the research report published on December 18, 2024 of the previous year 2024.
Cantor Fitzgerald, on the other hand, stated in their research note that they expect to see ESPR reach a price target of $8. The rating they have provided for ESPR stocks is “Overweight” according to the report published on December 17th, 2024.
BofA Securities gave a rating of “Underperform” to ESPR, setting the target price at $2.50 in the report published on June 20th of the previous year.
ESPR Trading at 9.35% from the 50-Day Moving Average
After a stumble in the market that brought ESPR to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -73.10% of loss for the given period.
Insider Trading
Reports are indicating that there were more than several insider trading activities at ESPR starting from Looker Benjamin, who sale 6,422 shares at the price of $1.15 back on Jun 17 ’25. After this action, Looker Benjamin now owns 401,241 shares of Esperion Therapeutics Inc, valued at $7,398 using the latest closing price.
Koenig Sheldon L., the President and CEO of Esperion Therapeutics Inc, sale 30,474 shares at $1.11 during a trade that took place back on Jun 17 ’25, which means that Koenig Sheldon L. is holding 1,541,488 shares at $33,796 based on the most recent closing price.
Stock Fundamentals for ESPR
Current profitability levels for the company are sitting at:
- -0.15 for the present operating margin
- 0.65 for the gross margin
The net margin for Esperion Therapeutics Inc stands at -0.59. The total capital return value is set at -0.75.
Based on Esperion Therapeutics Inc (ESPR), the company’s capital structure generated -2.32 points at debt to capital in total, while cash flow to debt ratio is standing at -0.34. The debt to equity ratio resting at -0.7. The interest coverage ratio of the stock is -0.62.
Currently, EBITDA for the company is 7.57 million with net debt to EBITDA at -2.07. When we switch over and look at the enterprise to sales, we see a ratio of 1.51. The receivables turnover for the company is 3.19for trailing twelve months and the total asset turnover is 0.8. The liquidity ratio also appears to be rather interesting for investors as it stands at 1.18.
Conclusion
In summary, Esperion Therapeutics Inc (ESPR) has had a bad performance as of late. Analysts have mixed opinions on the stock, with some viewing it as a “buy” and others as a “hold”. It is worth mentioning that the stock is currently trading in close proximity to its 50-day moving average and its 52-week high.
